Altimmune, Inc. (ALT) Stock Forecast
ALT analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.60 / 5 from 10 analysts
- Price target
- $17.11 average of analyst targets
- Upside to target
- +677.8% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.14
- 52-week range
- $2.20 – $6.18
ALT analyst ratings
10 analystsNumber of analysts at each rating.
ALT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ALT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.14 | −$0.15 | −$0.12 | −$0.21 | +34.9% | 6 |
| Current fiscal year (2026) | −$0.59 | −$0.65 | −$0.53 | −$1.00 | +41.2% | 6 |
| Next fiscal year (2027) | −$0.67 | −$0.88 | −$0.47 | −$0.59 | −13.6% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ALT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | −100.0% | 9 |
| Current fiscal year (2026) | $0 | $0 | $0 | −100.0% | 9 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 9 |
ALT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ALT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.17 | −$0.13 | −$0.14 | −$0.14 | −$0.14 | −18.2% | 0 up · 0 down |
| Current fiscal year (2026) | −$0.71 | −$0.57 | −$0.59 | −$0.59 | −$0.59 | −17.0% | 0 up · 0 down |
| Next fiscal year (2027) | −$0.86 | −$0.69 | −$0.67 | −$0.67 | −$0.67 | −22.2% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ALT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ALT beat in 10 of 12.
What analysts expect from ALT
10 analysts cover Altimmune; their consensus rating is strong buy (4.60 on a 1–5 scale, where 5 is a strong buy). The average price target is $17.11, 677.8% above the latest close of $2.20. Analysts expect earnings of −$0.59 per share for 2026, +41.2% from a year earlier. For 2027 the average estimate is −$0.67 per share. Altimmune beat the EPS estimate in 10 of the last 12 quarters.
Related: ALT income statement, ALT key metrics, ALT chart. See the ALT stock overview for the latest quote and news.
ALT forecast FAQ
What is Altimmune's price target?
The average analyst price target for Altimmune is $17.11, 677.8% above the latest close of $2.20.
Is Altimmune a buy, hold or sell?
Of 10 analysts covering Altimmune, 7 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Altimmune's EPS forecast?
Analysts forecast −$0.59 per share for 2026 (range −$0.65 to −$0.53); for 2027 the estimate is −$0.67.
When does Altimmune report earnings?
Altimmune is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.14.
Does Altimmune usually beat earnings estimates?
Altimmune reported EPS at or above the analyst estimate in 10 of the last 12 quarters.